Title:Antiobesity Drug Discovery Research: In vitro Models for Shortening the
Drug Discovery Pipeline
Volume: 25
Issue: 6
Author(s): Radheshyam, Priyanka Gauniya, Mona Semalty and Ajay Semalty*
Affiliation:
- Department of Pharmaceutical Sciences, Hemwati Nandan Bahuguna Garhwal University (A Central University) Srinagar
(Garhwal), Uttarakhand, India
Keywords:
Pancreatic lipase inhibition, obesity and overweight, BMI, cell lines, preclinical tests, weight management, antiobesity drugs.
Abstract: Obesity is a growing global health problem, leading to various chronic diseases. Despite
standard treatment options, the prevalence of obesity continues to rise, emphasizing the need
for new drugs. in vitro methods of drug discovery research provide a time and cost-saving platform
to identify new antiobesity drugs. The review covers various aspects of obesity and drug discovery
research using in vitro models. Besides discussing causes, diagnosis, prevention, and treatment,
the review focuses on the advantages and limitations of in vitro studies and exhaustively
covers models based on enzymes and cell lines from different animal species and humans. In contrast
to conventional in vivo animal investigations, in vitro preclinical tests using enzyme- and cell
line-based assays provide several advantages in development of antiobesity drugs. These methods
are quick, affordable, and provide high-throughput screening. They can also yield insightful information
about drug-target interactions, modes of action, and toxicity profiles. By shedding light on
the factors that lead to obesity, in vitro tests can also present a chance for personalized therapy.
Technology will continue to evolve, leading to the creation of more precise and trustworthy in
vitro assays, which will become more and more crucial in the search for novel antiobesity medications.
